BioClin has been acquired by Trimb Healthcare
December 2018 — Orange Pearl International has sold BioClin, a leading healthcare products company, to Trimb Healthcare AB, a Swedish pharmaceutical company.
Based in the Netherlands, BioClin sells products to provide direct treatment and relief for women’s intimate health discomforts. The company’s product portfolio consists of Multi-Gyn, a complete range for treating intimate discomforts and Multi-Mam, a product range of self-care products for mothers and babies. BioClin’s brands are growing rapidly and are sold in pharmacies and drugstores in over 60 countries worldwide.
Trimb Healthcare is rapidly growing pharmaceutical company with a focus on sales, marketing and development of prescription-free OTC pharmaceuticals and consumer healthcare products.
Our role in the transaction
Oaklins' team in the Netherlands acted as the exclusive sell-side advisor to the shareholders of BioClin in this transaction.
Talk to the deal team
Related deals
Valuation advisory has been provided to a co-investor in VDK
EMK Capital has transferred VDK Groep B.V. from EMK Capital Partners Fund I into the newly established US$1.4 billion single-asset continuation fund, the EMK VDK Partnership Fund, alongside a co-investment from EMK Capital Partners Fund III. The transaction, co-led by LGT Capital Partners and Coller EQT, provides existing investors with the opportunity to retain their exposure to VDK while securing additional capital to support the company’s continued growth and buy-and-build strategy.
Learn moreBe-Cloud has been acquired by PSG Equity
Be-Cloud, backed by B&Capital since 2021, has been acquired by PSG Equity, a leading growth equity firm specializing in software and technology-enabled services. The transaction marks the full exit of B&Capital and the reinvestment of Be-Cloud’s founders, Lenny and Sébastien Vercruysse, alongside PSG Equity.
Learn moreMattina Holding has sold a 5% stake in Gens Aurea via accelerated bookbuild
Mattina Holding S.A. (DVC Partners) has sold a 5% stake in Italian company Gens Aurea S.p.A. through an accelerated bookbuild, raising approximately US$69.96 million.
Learn more